Weekly Investment Analysts’ Ratings Changes for Entellus Medical (ENTL)

Several analysts have recently updated their ratings and price targets for Entellus Medical (NASDAQ: ENTL):

  • 7/14/2017 – Entellus Medical was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 7/12/2017 – Entellus Medical had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 7/11/2017 – Entellus Medical was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. “
  • 7/8/2017 – Entellus Medical was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/5/2017 – Entellus Medical was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. “
  • 6/2/2017 – Entellus Medical was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.

Entellus Medical, Inc. (NASDAQ:ENTL) opened at 17.31 on Tuesday. The firm’s 50-day moving average price is $15.63 and its 200 day moving average price is $15.13. The firm’s market cap is $379.37 million. Entellus Medical, Inc. has a 12-month low of $11.47 and a 12-month high of $22.63.

Entellus Medical (NASDAQ:ENTL) last issued its earnings results on Wednesday, May 3rd. The medical technology company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.04. Entellus Medical had a negative net margin of 39.02% and a negative return on equity of 60.56%. The firm had revenue of $19.11 million for the quarter, compared to analyst estimates of $19.61 million. During the same quarter last year, the business posted ($0.37) earnings per share. The company’s quarterly revenue was up 13.0% on a year-over-year basis. Analysts forecast that Entellus Medical, Inc. will post ($1.35) earnings per share for the current fiscal year.

In other Entellus Medical news, insider Robert S. White purchased 10,000 shares of the business’s stock in a transaction dated Monday, May 8th. The shares were bought at an average price of $12.24 per share, for a total transaction of $122,400.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brent Moen purchased 6,100 shares of the business’s stock in a transaction dated Monday, May 8th. The shares were acquired at an average price of $12.21 per share, for a total transaction of $74,481.00. The disclosure for this purchase can be found here. Insiders acquired 17,700 shares of company stock worth $216,625 in the last 90 days. Company insiders own 9.10% of the company’s stock.

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

What are top analysts saying about Entellus Medical Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Entellus Medical Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit